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IntroductIon
Cerebral cavernous malformations (CCMs) are central ner-
vous system vascular anomalies that lead to significant mor-
bidity and mortality (Golden et al., 2015). CCMs affect ∼1 
of 200 humans and cause a lifelong risk of stroke and other 
neurological sequelae for which there is no pharmacologic 
therapy. Loss-of-function mutations of three genes (KRTI1, 
CCM2, and PDCD10) are associated with development of 
venous capillary dysplasias with disrupted junctions, leading 
to hemorrhage and increased vascular permeability (Mikati 
et al., 2015) characteristic of CCM (D’Angelo et al., 2011; 
McDonald et al., 2014). The KRIT1+/− genotype is the most 
common cause of the familial form of CCM (Tanriover et al., 
2013). In mice, timed endothelial-specific inactivation of Krit1 
results in cerebellar and retinal vascular lesions that are similar 
to those in CCM patients (Boulday et al., 2011; Maddaluno et 
al., 2013; Cuttano et al., 2016). These mouse studies, in com-
bination with the finding of a “second hit” on the normal 
KRIT1 allele in human CCM endothelial cells (McDonald 
et al., 2011) indicate that a complete loss of KRIT1 function 
causes endothelial cell–autonomous CCM formation.
The consequences of loss of endothelial KRIT1 include 
abnormal angiogenesis (Whitehead et al., 2004; Boulday et 
al., 2011), dysregulation of endothelial metalloproteinases 
(Zhou et al., 2015), increased expression of the transcription 
factors KLF2 and KLF4 (Maddaluno et al., 2013; Renz et al., 
2015; Zhou et al., 2015), and alterations in signaling pathways 
such as Notch (Wüstehube et al., 2010), vascular endothe-
lial growth factor (VEGF; DiStefano et al., 2014), and Rho/
Rho kinase (Whitehead et al., 2009; Stockton et al., 2010). In 
addition, increased cell migration caused by disruption of en-
dothelial apical-basal polarity (Lampugnani et al., 2010) and 
endothelial-to-mesenchymal transition (Maddaluno et al., 
2013) have been recently reported to be features of CCMs. 
Changes in gene expression associated with these phenotypic 
changes include increased expression of the transcription fac-
tors KLF2 and KLF4 (Renz et al., 2015; Zhou et al., 2015) 
and mesenchymal genes (Maddaluno et al., 2013; Cuttano et 
al., 2016); however, a detailed picture of the early changes in 
gene expression that follow loss of KRIT1 has been lack-
ing. Here we perform genome-wide transcriptome analysis 
of brain microvascular endothelial cells (BMECs) after acute 
Krit1 inactivation and describe a signature of mRNA changes 
primarily affecting genes involved in cardiovascular develop-
ment. A striking finding was the dramatic suppression of a 
potent endogenous angiogenesis inhibitor, TSP1, which we 
ascribe to KLF2- and KLF4-mediated repression of the gene 
encoding TSP1, Thbs1. Reduced TSP1 expression contrib-
KrIt1 mutations are the most common cause of cerebral cavernous malformation (ccM). Acute Krit1 gene inactivation in 
mouse brain microvascular endothelial cells (BMEcs) changes expression of multiple genes involved in vascular development. 
these changes include suppression of thbs1, which encodes thrombospondin1 (tSP1) and has been ascribed to KLF2- and 
KLF4-mediated repression of thbs1. In vitro reconstitution of tSP1 with either full-length tSP1 or 3tSr, an anti-angiogenic 
tSP1 fragment, suppresses heightened vascular endothelial growth factor signaling and preserves BMEc tight junctions. Fur-
thermore, administration of 3tSr prevents the development of lesions in a mouse model of ccM1 (Krit1EcKo) as judged by 
histology and quantitative micro-computed tomography. conversely, reduced tSP1 expression contributes to the pathogenesis 
of ccM, because inactivation of one or two copies of thbs1 exacerbated ccM formation. thus, loss of Krit1 function disables 
an angiogenic checkpoint to enable ccM formation. these results suggest that 3tSr, or other angiogenesis inhibitors, can be 
repurposed for tSP1 replacement therapy for ccMs.
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utes to the pathogenesis of CCMs, because loss of one or 
two copies of Thbs1 exacerbated CCM formation. Replen-
ishing TSP1 in vitro with either full-length TSP1 or 3TSR, 
an anti-angiogenic TSP1 fragment, prevented the disruption 
of BMEC tight junctions, a phenotypic result of Krit1 inac-
tivation. Administration of 3TSR prevented disruption of in-
tercellular junctions in Krit1ECKO mice in part because of the 
capacity of 3TSR to inhibit VEGF signaling. Administration 
of 3TSR inhibited formation of CCMs in Krit1ECKO mice. 
Thus, loss of expression of TSP1, a key angiogenic check-
point, plays an important role in pathogenesis of CCM, and 
repurposing 3TSR or other angiogenesis inhibitors may pro-
vide a new approach to inhibit CCM development.
rESuLtS
Genetic inactivation of Krit1 inhibits expression of tSP1
To elucidate the pathogenesis of CCM, we used genome-wide 
RNA sequencing (RNA-seq) to characterize the transcrip-
tome of primary BMECs after acute genetic inactivation of 
Krit1. BMECs were isolated from mice bearing floxed al-
leles of Krit1 (Krit1fl/fl) and an endothelial-specific tamox-
ifen-regulated Cre recombinase (Pdgfb-iCreERT2; Claxton 
et al., 2008). Treatment of Krit1fl/fl-Pdgfb-iCreERT2 BMECs 
with 5 µM-hydroxy-tamoxifen deleted Krit1 (Krit1ECKO) and 
reduced KRIT1 mRNA and protein by >90% within 5 d 
compared with hydroxy-tamoxifen–treated Krit1fl/fl BMECs. 
Deep sequencing of cDNA from Krit1ECKO and Krit1fl/fl 
BMECs (Fig. S1) revealed that acute loss of brain endothe-
lial KRIT1 caused a dramatic change in gene expression in 
BMECs. We identified 334 genes differentially expressed be-
tween Krit1ECKO and Krit1fl/fl BMECs (corrected P < 0.05, 
≥2.5-fold change). Gene ontology analysis of the differen-
tially expressed genes indicated significant enrichment for 
terms related to cardiovascular development (P < 3.2 × 10−5; 
Fig. 1 A). Among genes known to be important in cardiovas-
cular development were up-regulation of Klf2 and Klf4, two 
transcription factors recently implicated in CCM pathogen-
esis (Maddaluno et al., 2013; Renz et al., 2015; Zhou et al., 
2015; Cuttano et al., 2016; Fig. 1 B). Among the most notable 
changes were an ∼75% decrease in expression of genes en-
coding secreted proteins or receptors that regulate angiogen-
esis, including Thbs1 (whose protein product is TSP1), Cxcr4, 
Bmp2, and Tgfb2 (Fig.  1, B and C). The changes in TSP1 
mRNA levels were associated with reduced TSP1 protein ex-
pression (∼3-fold decrease) in Krit1ECKO BMECs (Fig. 1 D).
To confirm these reductions in potential extracellular 
regulators of angiogenesis in vivo, we isolated brain micro-
vasculature from tamoxifen-treated neonatal Krit1ECKO or 
Krit1fl/fl mice and quantified mRNA with real-time quan-
titative PCR (RT-qPCR). Consistent with results observed 
in vitro, TSP1 and CXCR4 mRNA levels in freshly isolated 
brain microvasculature were reduced in postnatal day 7 (P7) 
Krit1ECKO mice (Fig. 1 E). In sharp contrast, we did not ob-
serve significant changes in BMP2 or TGFβ2 mRNA abun-
dance (Fig. 1 E). We focused on TSP1 because reduced TSP1 
mRNA expression was confirmed in vivo, TSP1 is an endog-
enous anti-angiogenic protein, and TSP1 fragments and an-
alogues have been developed as potential cancer therapeutic 
agents (Zhang and Lawler, 2007; Lawler and Lawler, 2012). 
We confirmed that the reduction in mRNA was reflected in 
reduced TSP1 protein abundance in freshly isolated brain mi-
crovasculature after genetic inactivation of endothelial Krit1 
(Fig.  1  F). Furthermore, there was a dramatic reduction in 
in situ TSP1 protein staining in CD31-positive endothelial 
cells in lesions of Krit1ECKO mice in comparison to Krit1fl/fl 
littermates (Fig. 1, G and H). Loss of TSP1 expression also 
occurs during the pathogenesis of human CCM, because 
there was a dramatic decrease in endothelial TSP1 staining 
in human CCM lesions in comparison to a lesion-free brain 
tissue (Fig. 2 A), and silencing KRIT1 in human endothelial 
cells led to reduced TSP1 expression in HUV ECs (Fig. 2, B 
and C). Thus, inactivation of Krit1 in BMECs leads to early 
reductions in TSP1 mRNA and protein expression in vitro 
and in vivo, suggesting a role for the reduction of this se-
creted anti-angiogenic protein in the pathogenesis of CCM.
Altered tight junctions are an early event 
that follows loss of KrIt1
Because TSP1 is a large (∼450 kD) glycoprotein, we sought 
an in vitro intermediate phenotype to assess the effect of 
TSP1 reconstitution. Disruption of cell–cell junctions and 
increased vascular permeability are prominent features of 
CCM in humans (Tanriover et al., 2013; Mikati et al., 2015), 
and silencing of KRIT1 leads to disruption of intercellular 
junctions in HUV ECs (Glading et al., 2007). We examined 
the time course of altered cell–cell junctions in cultured 
BMECs after acute genetic inactivation of Krit1. There was 
striking loss of tight junction proteins ZO-1 and claudin-5 
from BMEC junctions within 5 d of 4-hydroxy-tamoxifen 
treatment, an early time after the concentration of KRIT1 
protein and mRNA were decreased (Fig. 3 A and Fig. S2). 
Furthermore, immunoblotting revealed a 40–50% reduction 
in ZO-1 and claudin-5 protein abundance after inactivation 
of Krit1 in BMECs (Fig. 3 B). In contrast, at this early time 
point, the small decreases in vascular endothelial cadherin 
(VE-cadherin) protein abundance and distribution were not 
statistically significant (Fig.  3, A and B). To assess whether 
similar changes were observed at early times in lesion evo-
lution in vivo, we examined the endothelial distribution of 
these junctional proteins in the brains of P7 Krit1ECKO mice. 
ZO-1 and claudin-5 staining were markedly reduced in the 
dilated early CCM in these mice, whereas both tight junc-
tion proteins were abundant in normal vessels from Krit1ECKO 
and Krit1fl/fl littermates (Fig. 3, C and D). Furthermore, there 
were reduced levels of ZO-1 and claudin-5 in microvascula-
ture isolated from the cerebellum of P7–P10 Krit1ECKO mice 
as assessed by immunoblotting (Fig. 3 E). We did not observe 
significant changes in VE-cadherin protein levels in early le-
sions in Krit1ECKO (P7–P10) mice. Similar changes were seen 
in Krit1ECKO mouse retina (Fig. 3, F–H), a tissue that enables 
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precise temporal and spatial assessment of vascular develop-
ment (Pitulescu et al., 2010). Collectively, these data show 
that changes in tight junctions, which are features of CCM, 
are early abnormalities that follow loss of KRIT1 in BMECs. 
Such changes could therefore represent an intermediate phe-
notype to assess potential interventions in CCM pathogenesis.
reconstitution of tSP1 prevents the loss of tight junctions 
that follows inactivation of Krit1
Having shown that altered tight junctions are a result of loss 
of KRIT1 both in vitro and in vivo, we assessed the effect 
of the addition of exogenous mouse TSP1 on this pheno-
type in vitro. Addition of 5 nM TSP1 prevented the loss of 
Figure 1. Loss of KrIt1 inhibits the expression of tSP1. (A) Genome-wide RNA-seq from three independent biological replicates followed by gene 
ontology analysis of genes differentially expressed in Krit1ECKO BMECs compared with Krit1fl/fl BMECs. Each term listed was the top term in a cluster of related 
terms, and the corrected p-values were calculated according to Benjamini’s method (Huang et al., 2009). (B) Expression levels of differentially expressed 
genes represented on a scatter plot; fragments per kilobase of transcript per million mapped reads (FPKM) of individual transcripts are represented on a 
log2 scale. A few of the most highly suppressed and up-regulated genes are labeled. (C) RT-qPCR confirmation of RNA-seq–identified marked decrease in 
mRNA of extracellular regulators of angiogenesis in Krit1ECKO BMECs compared with Krit1fl/fl BMECs (SEM, n = 3). (D) Quantification of TSP1 protein from 
three independent biological replicates in Krit1ECKO (KO) and in Krit1fl/fl (Flox) BMECs (SEM, n = 3). (E) RT-qPCR analysis of isolated brain microvasculature in 
Krit1ECKO compared with Krit1fl/fl littermate controls (SEM, n = 3). (F) Quantification of TSP1 protein from freshly isolated brain microvasculature in Krit1ECKO 
(KO) compared with Krit1fl/fl (Flox) littermate controls (SEM, n = 3). (G) Confocal microscopy of cerebellar cortex stained for TSP1 (red) and endothelial 
specific marker PEC AM1 (green); DAPI staining (blue) was used to reveal nuclei (n = 3). (H) Higher-magnification images of boxed areas in G. TSP1 protein 
expression was decreased in CCM from Krit1ECKO mice (arrows). Asterisks, vascular lumen of CCM lesions. Bars: (G) 100 µm; (H) 25 µm. *, P < 0.05; **, P < 
0.01; ***, P < 0.001; determined by Student’s t test. Data in A–H are representative of three independent experiments.
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ZO-1 from BMEC tight junctions after Krit1 inactivation 
(Fig. 4 A). In contrast, prior studies showed that much higher 
doses of TSP-1 (∼200 nM) could destabilize junctions (Garg 
et al., 2011). TSP1 is a modular protein and a recombinant 
fragment containing three type I repeats (3TSR) that ac-
counts for much of the anti-angiogenic activity through its 
capacity to engage both CD36 and integrins (Short et al., 
2005; Lawler and Lawler, 2012). Treatment of BMEC with 
20 nM recombinant 3TSR also prevented loss of ZO-1 from 
cell–cell junctions (Fig. 4 B) and the reduction in ZO-1 pro-
tein abundance that followed deletion of Krit1 (Fig. 4, C and 
D). These effects of 3TSR were also seen in vivo. Treatment 
of Krit1ECKO mice with 1.6 mg/kg 3TSR on two succeeding 
days increased ZO-1 expression in the cerebellum (Fig. 4 E). 
These data show that replacement of TSP1 can prevent the 
effects of Krit1 deletion on the distribution and abundance 
of ZO-1 in brain endothelium and that an anti-angiogenic 
domain of TSP1 (3TSR) is sufficient for this activity.
tSP1 replacement with 3tSr antagonizes increased VEG Fr2 
phosphorylation that follows inactivation of Krit1
VEGF signaling is enhanced in KRIT1-depleted endothelial 
cells (DiStefano et al., 2014) and can contribute to the dis-
ruption of interendothelial junctions (Morin-Brureau et al., 
2011; Argaw et al., 2012) and capillary dilatation that occur in 
CCM (Jung et al., 2003). Therefore, we assessed the effect of 
loss of brain endothelial KRIT1 on VEG FR2 phosphorylation 
as an indicator of VEG FR2 signaling. Immunocytochemistry 
revealed elevated levels of VEG FR2-Tyr1175 phosphorylation 
in Krit1ECKO BMECs (Fig. 4, F and G). Treatment of BMECs 
with 3TSR prevented the increased VEG FR2-Tyr1175 phos-
phorylation that followed Krit1 deletion (Fig. 4, F and G). 
Furthermore, silencing KRIT1 in human endothelial cells 
increased VEG FR2 phosphorylation; this was prevented by 
3TSR (Fig. S3), and a VEG FR2 antagonist ameliorated the 
effects of KRIT1 deletion on tight junctions (Fig. S3). 3TSR 
also prevented increased VEG FR2-Tyr1175 phosphorylation in 
Figure 2. decreased human endothelial tSP1. 
(A) Immunofluorescent staining of TSP1 (red) and 
collagen IV (green) of human CCM and lesion-free 
brain tissue. Arrowheads, capillary; arrows, venule; 
asterisks, vascular lumen of CCM lesions. Bar, 
100 µm (n = 2). (B and C) HUV ECs were trans-
duced with shKrit1 or shControl using lentivirus. 
(B) KRIT1-depleted HUV ECs expressed ∼50% as 
much TSP1 protein as control cells (SEM, n = 3). 
(C) KRIT1 shRNA 55% decrease in KRIT1 mRNA as 
determined by RT-qPCR (SEM, n = 4). **, P < 0.01; 
***, P < 0.001; determined by Student’s t test. Data 
in A is from two independent experiments, and 
data in B and C are representative of three or four 
independent experiments.
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the brains of Krit1ECKO mice (Fig. 4 H). 3TSR can also pro-
mote TGF-β activation; however, we noted no effect of 3TSR 
on expression of TGF-β–regulated genes or in SMAD3 phos-
phorylation in Krit1ECKO BMECs (Fig. S4). Thus, 3TSR limits 
the increased VEG FR2 signaling that follows loss of endothe-
lial KRIT1, an effect that can account for both stabilization of 
tight junctions and prevention of capillary dilation in CCM.
tSP1 replacement with 3tSr prevents ccM
Visual inspection of the hindbrains of neonatal 3TSR-treated 
Krit1ECKO mice compared with vehicle-treated littermate 
Krit1ECKO controls (Fig. 5 A) revealed a notable reduction in 
the number and size of vascular lesions (Fig. 5 B). A similar 
marked reduction in histologically typical CCMs was ob-
served in 3TSR-treated Krit1ECKO mice (Fig. 5 C), and a sim-
Figure 3. Altered tight junctions are an early phenotypic consequence of Krit1 inactivation. (A) Representative confocal images of ZO-1 (red), 
claudin5 (CLDN5; turquoise), and VE-cadherin (green) staining in primary BMEC Krit1ECKO or control Krit1fl/fl BMECs. Nuclei were counterstained with DAPI 
(blue; n = 4). Arrows indicate loss of tight junctions but not adherence junctions. (B) Quantification of brain endothelial ZO-1, claudin5, and VE-cadherin 
protein as assessed by Western blot analysis in Krit1ECKO compared with Krit1fl/fl BMEC controls (SEM, n = 3 or 4). (C) Confocal microscopy of cerebellar 
cortex at P7 stained with anti-PEC AM1 (green). (D) Higher-magnification images of boxed areas in C stained for ZO-1 (red), claudin5 (turquoise), and 
PEC AM1 (green). Arrows, staining of tight junction proteins ZO-1 and claudin5; asterisks, vascular lumen of CCM (n = 3). (E) Quantification of brain en-
dothelial ZO-1, claudin5, and VE-cadherin protein abundance in freshly isolated cerebellar microvasculature in Krit1ECKO compared with Krit1fl/fl littermate 
controls (SEM, n = 3 or 4). (F) Maximum-intensity projection of whole-mount P7 retinal vasculature at the angiogenic growth front stained for ZO-1 (red), 
claudin5 (turquoise), and an endothelial marker, isolectin B4 (green). (G) Higher-magnification images of boxed areas in F show staining for ZO-1 (red), 
claudin5 (turquoise), and isolectin B4 (green). (H) Quantification of ZO-1 and claudin5 protein expression in retinal vasculature at the angiogenic front in 
Krit1ECKO compared with Krit1fl/fl littermate controls (SEM, n = 6 mice per group). Bars: (A) 50 µm; (C) 100 µm; (D, F, and G) 25 µm. *, P < 0.05; **, P < 0.01; 
determined by Student’s t test. Data in A–H are representative of at least three independent experiments.
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ilar reduction was noted in retinal lesions (Fig. 5, D and E). 
Importantly, 3TSR administered into the retroorbital venous 
plexus was able to reach the CCM (Fig. 5, F and G), suggest-
ing that it could act locally during CCM development. To 
quantify CCM formation, we imaged P7 hindbrains using 
contrast-enhanced, high-resolution x-ray micro-computed 
Figure 4. reconstitution of tSP1 prevents the tight junction loss that follows inactivation of Krit1. (A) 5 nM mouse recombinant TSP1 (mrTSP1) 
was added to cultured Krit1ECKO BMEC 72 h after initial treatment with 4-hydroxy-tamoxifen. Note continuous ZO-1 junctional staining in TSP1-treated 
Krit1ECKO BMEC (arrowheads), resembling the appearance of Krit1fl/fl BMEC. In sharp contrast, ZO-1 staining was reduced and discontinuous (arrows) in 
vehicle-treated Krit1ECKO. (B) Treatment with an anti-angiogenic domain (20 nM), 3TSR. The arrows in Krit1ECKO BMEC indicate immunostaining for ZO-1 that 
is punctate and reduced at the cell–cell contacts. Treatment with 3TSR prevented loss of ZO-1 protein from tight junctions in Krit1ECKO BMEC (arrowheads). 
(C) Quantification of ZO-1 protein expression in BMEC. Krit1ECKO or control Krit1fl/fl BMEC treated with TSP1, 3TSR, or vehicle as indicated (SEM, n = 3). (D) 
ZO-1 protein levels as determined by Western blot analysis in Krit1ECKO and Krit1fl/fl BMEC in the presence or absence of 20 nM 3TSR (SEM, n = 3). Bottom 
row is actin loading control. (E) Quantification of ZO-1 protein expression in cerebellar tissue in Krit1ECKO and control Krit1fl/fl mice treated with 3TSR or 
vehicle (SEM, n = 4 mice in each group). Bottom row is actin loading control. (F) VEG FR2-Tyr1175 phosphorylation in primary BMEC Krit1ECKO or control Krit1fl/fl 
BMECs treated with 3TSR or vehicle. Nuclei were counterstained with DAPI (blue). (G) Quantification of VEG FR2-Tyr1175 phosphorylation in BMECs is shown 
as integrated density in Krit1ECKO and Krit1fl/fl controls in the presence or absence of 20 nM 3TSR (SEM, n ≥ 47 cells). (H) Quantification of VEG FR2-Tyr1175 
phosphorylation in cerebellar tissue in Krit1ECKO and control Krit1fl/fl treated with 3TSR or vehicle 30 min after VEGF treatment (75 µg/Kg), as assessed by 
Western blot analysis (SEM, n = 4 mice in each group). Bar: (A and B) 50 µm; (F) 25 µm. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus vehicle-treated Krit1ECKO; 
determined by one-way ANO VA followed by Tukey’s post hoc test (C and G) or Student’s t test (D, E, and H). Data in A–H are representative of at least three 
independent experiments.
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tomography (micro-CT), and measured lesion volumes using 
semiautomated software. 3TSR-treated Krit1ECKO mouse 
hindbrains exhibited near-complete prevention of CCM 
compared with vehicle-treated Krit1ECKO littermates, as as-
sessed by hindbrain micro-CT imaging (Fig. 6 A). Blinded 
measurement of total CCM lesion volume (Fig. 6 B) con-
firmed the dramatic reduction in CCM as a consequence of 
3TSR administration. Thus, replacement of TSP1 with 3TSR 
inhibited CCM formation.
To assess the role of endogenous TSP1 in limiting CCM 
pathogenesis, we examined the impact of genetic inactivation 
of Thbs1 in Krit1ECKO mice. Micro-CT analysis of Krit1ECKO; 
Thbs1+/− mice revealed an ∼80% increase in the volume 
of CCM lesions relative to Krit1ECKO;Thbs1+/+ littermates, 
whereas the surviving Krit1ECKO;Thbs1−/− mice exhibited 
an ∼200% increase in CCM lesion volume (Fig.  6, A and 
B). Furthermore, there was a statistically significant reduction 
in survival of Krit1ECKO;Thbs1+/− versus Krit1ECKO;Thbs1+/+ 
mice (Fig. 6 C). These data show that TSP1 limits the forma-
tion of CCMs and that replacement of the loss of TSP1 with 
an anti-angiogenic fragment can prevent CCMs. Thus, the 
reduced expression of TSP1 that follows Krit1 inactivation 
contributes to CCM lesion pathogenesis.
KLF2 and KLF4 regulate expression of tSP1
Recent studies established the importance of elevated expres-
sion of KLF2 and KLF4 transcription factors in the cardio-
vascular effects of loss of KRIT1 expression (Maddaluno et 
al., 2013; Renz et al., 2015; Zhou et al., 2015, 2016; Cuttano 
et al., 2016). Furthermore, elevation of KLF2 and KLF4 ex-
pression precedes an increase in Wnt-β-catenin signaling or 
endothelial-to-mesenchymal transition (Zhou et al., 2016). 
Figure 5. tSP1 derivative, 3tSr, prevents ccMs and retinal vascular lesions in Krit1ECKO mice. (A) Experimental protocol: vehicle or 3TSR (1.6 mg/
Kg) was administered by retroorbital plexus injection at P5 and P6, and brains and retinas were analyzed at P7. (B) Prominent lesions are present in the 
cerebellum of Krit1ECKO mice, whereas administration of 3TSR suppressed lesion formation. (C) Hematoxylin and eosin staining of cerebellar sections from 
Krit1ECKO mice after treatment with 3TSR or vehicle (n = 4 mice in each group). (D) Representative image of whole-mount P7 retinal vasculature at the 
angiogenic growth front. The marked area in Krit1ECKO whole-mount retina shows decreased areas of condensed vascular plexus in Krit1ECKO treated with 
3TSR compared with vehicle-treated Krit1ECKO littermates (SEM, n = 8 mice in each group). (E) Quantification of lesion coverage in Krit1ECKO mice treated with 
3TSR or Vehicle (SEM, n = 8 mice in each group). (F) Administered 3TSR is present in CCM. 3TSR was injected retroorbitally into a Krit1ECKO;Thbs1−/− mouse. 
After 30 min, the mouse was killed, and its cerebellar cortex was stained for 3TSR (red, using anti-TSP1 antibodies) and endothelial marker PEC AM1 (green); 
DAPI staining (blue) was used to reveal nuclei. 3TSR is observed in CCM. (G) Higher-magnification images of boxed areas in F. (F and G) Asterisks, vascular 
lumen of CCM. Bars: (B) 1 mm; (C and F) 100 µm; (D) 200 µm; (G) 50 µm. ***, P < 0.001 versus vehicle-treated Krit1ECKO mice; determined by Student’s t test.
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We noted that expression of both KLF2 and KLF4 was in-
creased in freshly isolated brain microvasculature of Krit1ECKO 
mice at a time that roughly coincided with the decrease in 
TSP1 and ZO-1 mRNA levels (Fig. 7, A and B). Moreover, 
in retinas, there was marked up-regulation of nuclear KLF4 
at areas of condensed peripheral vascular plexus (Maddaluno 
et al., 2013) that showed pronounced reduction in TSP1 im-
munostaining at P7 (Fig. 7 C). Because KLF2 and KLF4 are 
central transcriptional drivers of flow-mediated athero- and 
thrombo-protective vascular responses (Lin et al., 2005; Zhou 
et al., 2012), and loss of these transcription factors in endo-
thelial cells is lethal in adult mice (Sangwung et al., 2017), 
we examined the effect of TSP1 and 3TSR on expression 
of these transcription factors. Neither TSP1 nor 3TSR pre-
vented the increase in KLF2 or KLF4 mRNA after Krit1 
inactivation in vitro (Fig. 7 D), and 3TSR did not do so in 
vivo (Fig. 7 E). Thus, exogenous addition of TSP1 or its an-
ti-angiogenic domain, 3TSR, can block vascular effects that 
follow loss of KRIT1 in spite of maintained elevation of 
KLF2 and KLF4 expression.
To test whether increased KLF2 or KLF4 was suffi-
cient for suppression of TSP1 expression, we used lentivi-
rus-mediated transduction to ectopically express KLF2 and 
KLF4 in human endothelial cells at levels similar to those 
that followed KRIT1 silencing (Fig. 7 F). Overexpression of 
KLF2 or KLF4 resulted in ∼15% or ∼30% decreases in TSP1 
mRNA, respectively (Fig.  7  G). Moreover, ectopic expres-
sion of KLF4 induced an ∼3.5-fold decrease in TSP1 pro-
tein levels in human endothelial cells (Fig. 7 H), whereas the 
KLF2-induced ∼1.5-fold decrease in TSP1 protein abundance 
was not statistically significant (Fig. 7 H). Collectively, these 
data suggest that the suppression of TSP1 expression is an im-
portant downstream effect of the elevation in KLF2 and KLF4 
that follows loss of KRIT1 (Fig. 7 I). Loss of the angiogenic 
checkpoint protein, TSP1, then leads to enhanced VEG FR2 
signaling that contributes to the pathogenesis of CCM.
dIScuSSIon
Here, we show that acute Krit1 inactivation in BMECs causes 
rapid changes in expression of genes involved in cardiovas-
cular development. Most notable is the dramatic suppression 
of TSP1, a potent endogenous angiogenesis inhibitor; this 
suppression is also seen in human CCM and follows the in-
crease in expression of transcription factors KLF2 and KLF4. 
Replenishing TSP1 with either full-length TSP1 or 3TSR, 
an anti-angiogenic TSP1 fragment, prevents the disruption 
of BMEC tight junctions, an early phenotypic consequence 
of loss of KRIT1. Rescue of tight junctions is ascribable to 
the capacity of 3TSR to prevent increased VEG FR2 phos-
phorylation in Krit1ECKO BMECs and mice. Administration 
Figure 6. tSP1 limits ccM formation in Krit1ECKO mice. (A) Prominent lesions are present in the cerebellum of Krit1ECKO mice, whereas administration 
of 3TSR suppressed lesion formation. Increased CCM lesions were observed in Krit1ECKO;Thbs1+/− and Krit1ECKO;Thbs1−/− mice. (B) Quantification of lesion 
volumes by micro-CT analysis from mice in experiment depicted in A. Controls were either vehicle-treated mice or untreated mice that had similar lesion 
volumes. All groups were compared with control Krit1ECKO mice (SEM, n > 16 mice in each group, except Krit1ECKO;Thbs1−/− mice (n = 3). (C) Survival of 
Krit1ECKO and Krit1ECKO;Thbs1+/− mice. The number of mice in each group is in parentheses. Statistical significance was analyzed by log-rank test for compar-
ing survival rates. *, P < 0.05, *** P < 0.001; determined by one-way ANO VA followed by Tukey’s post hoc test.
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Figure 7. tSP1 replacement does not suppress the rise in KLF2 and KLF4 after loss of KrIt1. (A and B) Analysis of TSP1, ZO-1, KLF2, and KLF4 mRNA 
levels by RT-qPCR in freshly isolated microvasculature from mice at P5 and P7 as indicated. Krit1fl/fl littermate controls, at each developmental stage, were 
used to calculate percentage increase or decrease in Krit1ECKO mice using the following formulas: % increase = 100 × (X − F)/F and % decrease = 100 × 
ABS[(F − X)/F], where X and F = mRNA abundance in Krit1ECKO and Krit1fl/fl BMECs, respectively (SEM, n = 4 or 6). (C) Representative confocal images of retinal 
vasculature stained for KLF4 (green), TSP1 (red), or isolectin B4 (turquoise). TSP1 is decreased and KLF4 is increased at areas of condensed vasculature (n = 
5 or 6 mice in each group). Bar, 25 µm. (D and E) Analysis of levels of KLF2 and KLF4 mRNA by RT-qPCR from Krit1ECKO BMEC (D) or cerebellar tissue from 
Krit1ECKO mice (E) treated with 3TSR, TSP1, or vehicle compared with Krit1fl/fl BMEC or Krit1fl/fl controls. Data are expressed as percentage increase or decrease 
in Krit1ECKO using the same formulas as in A and B (SEM, n = 3 or 4 in each group). (F) HUV ECs were transduced with lentivirus encoding shKrit1, KLF2, or 
TSP1 controls development of CCM | Lopez-Ramirez et al.3340
of 3TSR prevented the development of CCMs in Krit1ECKO 
mice as judged histologically and by quantitative micro-CT. 
Conversely, reduced Thbs1 gene dosage in Krit1ECKO mice 
increased the CCM lesion burden, demonstrating that endog-
enous TSP1 limits the pathogenesis of CCM. These studies 
reveal a critical mechanism in the pathogenesis of CCM and 
point to the possibility of repurposing 3TSR, or other angio-
genesis inhibitors, for therapy of CCM.
Inactivation of brain microvascular endothelial Krit1 
induced a rapid change in expression of genes that regulate 
cardiovascular development. We used primary BMECs and a 
conditional Cre recombinase to precisely control the time of 
deletion and analyzed gene expression at a time point when 
KRIT1 mRNA had just fallen to <90% of initial levels. Our 
data provide the first genome-wide view of the acute effects 
of loss of KRIT1 in the target cell for CCM formation. The 
dramatic changes in genes tied to the cell cycle and extracel-
lular matrix provide a molecular signature that explains the 
observed increased proliferation and extracellular matrix seen 
in lesions from CCM patients (Shenkar et al., 2007). We noted 
dramatic up-regulation of KLF2 and KLF4, transcription 
factors recently implicated in development of CCM lesions 
(Maddaluno et al., 2013; Renz et al., 2015, 2016; Cuttano et 
al., 2016). Furthermore, confirming recent findings (Zhou et 
al., 2016), we found few early changes in genes involved in 
endothelial-to-mesenchymal transition, a result explained by 
a recent report that these markers are elevated ∼15 d after 
Krit1 inactivation, downstream of the elevation of KLF4 
(Cuttano et al., 2016). We also found several KRIT1-regulated 
genes encoding secreted proteins and receptors (e.g., TSP1, 
CXCR4, BMP2, TGFb2, LRG1, and Dll1) that could mod-
ulate previously reported angiogenic remodeling (Whitehead 
et al., 2004, 2009; Boulday et al., 2011; Maddaluno et al., 
2013) and inflammation (Shenkar et al., 2007; e.g., TSP1, LBP, 
ADAM8, NOD2). Thus, this analysis provides new molecular 
clues about the pathogenesis of CCM.
A striking finding was an ∼75% reduction in TSP1 
mRNA and an ∼70% reduction in TSP1 protein. TSP1 is 
among the most potent and best-characterized endogenous 
inhibitors of angiogenesis. Up-regulation of expression of 
TSP1 during angiogenesis limits vascular density, thus serving 
as an angiogenic checkpoint to prevent neovascularization 
(Jiménez et al., 2000; Rodriguez-Manzaneque et al., 2001). 
Strikingly, in TSP1-null mice, angiogenic vessels are dramat-
ically dilated within tumors (Rodriguez-Manzaneque et al., 
2001; Velasco et al., 2009), thereby resembling early CCMs. 
Although loss of KRIT1 can destabilize adherens junctions 
(Glading and Ginsberg, 2010; Maddaluno et al., 2013), we 
find that loss of tight junctions occurs before loss of adherens 
junctions, thus mirroring the alterations in tight junctions in 
human CCM lesions (Schneider et al., 2011; Stamatovic et 
al., 2015). Replacement of TSP1 could prevent the loss of 
brain endothelial tight junctions that follows inactivation of 
Krit1 in vitro, indicating that disabling the TSP1 angiogenic 
checkpoint has a pathogenic role in the increased vascular 
permeability that characterizes CCMs (Tanriover et al., 2013; 
Mikati et al., 2015). Indeed, loss of TSP1 from brain endothe-
lium alters VEGF signaling (Rodriguez-Manzaneque et al., 
2001; Isenberg et al., 2009; Lawler and Lawler, 2012), which 
can contribute to disassembly of brain endothelial tight junc-
tions (Morin-Brureau et al., 2011; Argaw et al., 2012) and 
cerebrovascular dysfunction (Whitehead et al., 2009; Argaw et 
al., 2012). Our finding that loss of brain endothelial KRIT1 
led to increased levels of VEG FR2 phosphorylation and that 
VEGF inhibition preserves morphological tight junctions in 
Krit1ECKO mice are consistent with the findings that loss of 
KRIT1 increases VEGF signaling, and that VEG FR2 inhibi-
tors prevent the resulting increase in endothelial paracellular 
permeability (DiStefano et al., 2014). Thus, 3TSR prevention 
of increased VEG FR2 signaling in Krit1ECKO endothelial cells 
provides a cogent explanation for the capacity of 3TSR to 
reduce vascular dysmorphology in Krit1ECKO mice.
We previously showed that loss of KRIT1 leads to ac-
tivation of Rho kinase (ROCK), thereby increasing vascular 
leak (Stockton et al., 2010) and that blocking ROCK with 
inhibitors that are well tolerated in humans could amelio-
rate CCM (McDonald et al., 2012). Recent data suggest that 
ROCK activation during CCM formation is downstream of 
KLF2 elevation (Zhou et al., 2016). As shown here, KLF2 
and KLF4 suppress TSP1 expression, and 3TSR (Lawler and 
Lawler, 2012), which was relatively nontoxic in preclinical 
studies (Russell et al., 2015), prevents CCM without sup-
pressing KLF2 and KLF4. Moreover, ABT-510, a TSP-derived 
anti-angiogenic peptide, was well tolerated in phase I stud-
ies in humans (Hoekstra et al., 2005; Gietema et al., 2006). 
Importantly, 3TSR and ABT-510 lack the TSP1 epidermal 
growth factor (EGF) repeats that can disrupt cell–cell junc-
tions (Garg et al., 2011). Loss of endothelial KLF2 and KLF4 
is lethal (Sangwung et al., 2017), as is inactivation of MEKK3 
(Parmar et al., 2006; Hamik et al., 2007; Ohnesorge et al., 
KLF4, and the increase in KLF2 or KLF4 mRNA relative to cells transduced with lentivirus encoding GFP was measured by RT-qPCR (SEM, n = 4). (G) HUV 
ECs were transduced with lentivirus encoding ShKrit1, KLF2, or KLF4 as described in F, and the decrease of TSP1 mRNA levels was measured relative to cells 
transduced with EGFP control lentivirus (SEM, n = 4 or 5). (H) Analysis of TSP1 protein levels in HUV ECs transduced with lentivirus encoding KLF2 or KLF4 as 
assessed by Western blot analysis; lentivirus encoding GFP was used as a control (SEM, n = 4). White lines indicate intervening lanes have been spliced out. 
(I) Loss of endothelial KRIT1 increases expression of KLF2 and KLF4 transcription factors, contributing to CCM formation by downstream effects including 
suppressed TSP1 expression. 3TSR (TSP1 derivative) reduces CCM lesion formation by replacing functions of TSP1 such as blocking VEGF signaling. Loss of 
KRIT1 also leads to ROCK activation in a KLF2-dependent manner, and blocking ROCK can also ameliorate CCMs. Thus, blockade of these and other down-
stream targets of KLF2 and KLF4 may offer a general strategy to reduce CCM formation in humans. *, P < 0.05; ** P < 0.01; determined by Student’s t test.
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2010), which is upstream of the elevation of KLF2 (Zhou et 
al., 2016). Thus, we propose that identification of the down-
stream targets of KLF2 and KLF4 that mediate CCM for-
mation, such as ROCK activation and TSP1 suppression, can 
serve as a general strategy for discovery of agents that might 
act alone or synergistically to prevent these common vascular 
malformations (Fig. 7 I).
MAtErIALS And MEthodS
Genetically modified mice
Endothelial-specific conditional Krit1-null mice were gen-
erated by breeding transgenic mice expressing endotheli-
al-specific, Pdgfb promoter-driven, tamoxifen-regulated Cre 
recombinase, iCreERT2 (Claxton et al., 2008), in combination 
with loxP-flanked Krit1 exon 5 (Krit1fl/fl, a gift of Douglas A. 
Marchuk, Duke University, Durham, NC; Pdgfb-iCreERT2; 
Krit1fl/fl mice). All experiments were performed using aged 
matched Krit1fl/fl littermates on the same C57BL/6 back-
ground. TSP1-null (Thbs1tm1Hyn/J, Jackson Laboratory) mice 
were crossed with Pdgfb-iCreERT2; Krit1fl/fl mice to gen-
erate Pdgfb-iCreERT2; Krit1fl/fl; TSP1+/− mice. Mice were 
administered 50 µg tamoxifen (T5648; Sigma-Aldrich) by 
intragastric injection on P1, P2, and P3, inducing Cre activ-
ity and endothelial Krit1 gene inactivation in the littermates 
bearing the iCreERT2 (Krit1ECKO). These mice and control 
Krit1fl/fl mice were killed by decapitation for phenotypic 
analysis on the indicated postnatal days.
For 3TSR treatment, mice were randomized (by flip-
ping a coin) to TSR (1.6 mg/kg) or vehicle treatment. 10 μl 
3TSR was administered by retroorbital injection on P5 and 
P6 using a 28-gauge, 0.36 × 13-mm needle mounted on an 
insulin syringe (Ultra-Fine II; BD). 3TSR was prepared as de-
scribed previously (Miao et al., 2001). All animal experiments 
were performed in compliance with animal procedure pro-
tocols approved by the University of California, San Diego 
Institutional Animal Care and Use Committee.
Isolation and purification of primary BMEcs
Adult 2–4-mo-old mice were killed, and their brains were 
removed and dropped into ice-cold buffer A (10 mM Hepes, 
1× penicillin-streptomycin, and 0.5% BSA in DMEM). Me-
ninges and choroid plexus were removed, and brain tissue 
was minced with scissors. Tissue suspensions were centri-
fuged at 700 g for 5 min at 4°C, and the brain tissue pellet 
was digested with collagenase and dispase solution (DMEM 
containing 1 mg/ml collagenase/dispase [10269638001; 
Sigma-Aldrich], 20 units/ml DNase I [11284932001; Sigma- 
Aldrich], and 0.150 tosyl-lysine-chloromethyl-ketone [T7254; 
Sigma-Aldrich]) at 37°C for 1 h. After incubation, the brain 
tissue was triturated with Pasteur pipettes using different sized 
tips until a homogeneous suspension was obtained. This sus-
pension was centrifuged (700 g for 5 min at 4°C), and the 
pellet was resuspended in ice-cold buffer B (10 mM Hepes, 
1× penicillin streptomycin, and 25% BSA in DMEM). The 
suspension was centrifuged at 1000 g for 20 min at 4°C. The 
pellet containing microvascular fragments (heavier phase) un-
derwent a second collagenase and dispase digestion for 30 
min and was clarified by passage through a 70-µm mesh filter. 
BMECs were seeded onto collagen-coated plates and cul-
tured in EBM-2 medium supplemented with complements 
(hereafter termed EGM-2-BMEC medium) obtained from 
the manufacturer (Lonza) at the following concentrations: 
0.025% (vol/vol) recombinant human EGF, 0.1% (vol/vol) 
insulin-like growth factor, 0.1% (vol/vol) gentamicin, 0.04% 
(vol/vol) ascorbic acid, 0.04% (vol/vol) hydrocortisone, and 
20% (vol/vol) FBS. BMECs were cultured for 2 d in 10 µg/
ml puromycin and maintained in 2 µg/ml puromycin for 6 
d. Purified primary BMECs were routinely characterized for 
morphology and formation of adherens and tight junctions 
by immunofluorescence, for the presence of mRNA from en-
dothelial cell–specific genes, and for the absence of leukocyte, 
glia, and smooth muscle cell marker mRNAs.
Isolation of brain microvasculature
P5–P10 mice were killed. Brain and cerebellum were re-
moved into ice-cold buffer A. Four to five brains from tamox-
ifen-injected Krit1ECKO were pooled, and comparisons were 
performed with similar pools from littermate tamoxifen-in-
jected Krit1fl/fl mice. Brain tissue was minced with scissors 
and centrifuged at 700 g for 5 min at 4°C. The pellet was 
resuspended and incubated in ACK lysing buffer (10-548E; 
Lonza) for 5 min at room temperature to eliminate eryth-
rocytes. The resulting suspension was sedimented by cen-
trifugation (700 g, 5 min), and the pellet was digested with 
collagenase and dispase solution for 1 h at 37°C. The suspen-
sion was triturated and centrifuged at 700 g for 5 min at 4°C, 
and microvasculature was passed through a 70-µm mesh filter. 
Depletion of blood cell contaminants was performed using 
Dynabeads Untouched Mouse T cell kit (11413D; Thermo 
Fisher Scientific) according to the manufacturer’s protocol. 
For brains at P7 to P10, the tissue suspension was centrifuged 
at 700 g for 10 min at 4°C, and the pellet was resuspended 
in ice-cold buffer B and centrifuged at 1,000 g for 20 min 
at 4°C. Density-dependent centrifugation in BSA separates 
capillary fragments (heavier density) from myelin, neurons, 
astrocyte, and other brain-resident contaminants (lighter den-
sity). The capillary fragment phase was subjected to Percoll 
gradient as previously reported (Lopez-Ramirez et al., 2014). 
For brains at P5, the tissue suspension was centrifuged at 
700 g for 10 min at 4°C, and the pellet was resuspended in 
100 µl isolation buffer (PBS, pH 7.2, 0.5% BSA, and 2 mM 
EDTA) containing rat polyclonal antibody anti-mouse CD31 
microbeads (130-097-418; Miltenyi Biotec). After incubation, 
the cell suspension was washed using 7 ml isolation buffer and 
centrifuged at 1,000 g for 10 min. The supernatant was re-
moved, and the cell pellet was resuspended in 500 µl isolation 
buffer. CD31+ cells were sorted by applying cell suspension 
onto an LS column placed into a magnetic field according 
to the manufacturer’s protocol (130-042-401; Miltenyi Bio-
tec). Endothelial cell identity was confirmed by RT-qPCR of 
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mRNA from endothelial cell–specific genes and minor levels 
of leukocyte, glia, and smooth muscle cell marker mRNAs.
Genetic inactivation of KrIt1 in BMEcs
BMECs at passage 1–3 were maintained at 37°C in 95% air 
and 5% CO2, grown to 85% confluence, and treated for 48 h 
with 5  µM 4-hydroxy-tamoxifen (H7904; Sigma-Aldrich), 
after which the medium was replaced with medium lack-
ing 4-hydroxy-tamoxifen, and cells were harvested after 72 h 
in culture. For TSP1 and 3TSR addition experiments, after 
24 h in EGM-2-BMEC medium without serum containing 
0.5% BSA, 5 nM mrTSP1 (7859-TH; R&D Systems), 20 nM 
3TSR, or vehicle was added. After 48  h, a second dose of 
TSP1, 3TSR, or vehicle was added, and cells were harvested 
after an additional 24 h.
Immunofluorescence microscopy
BMECs were grown to confluence on collagen-coated cover 
glass (12-545-81; Thermo Fisher Scientific), and cells were 
fixed for 10 min at room temperature with 4% PFA in PBS, 
pH 7.4, and permeabilized with 0.5% Triton X-100 in PBS 
for 5 min. The slides were blocked with 0.5% BSA for 30 min 
and incubated with rabbit polyclonal antibody anti–ZO-1 
(1:80, 61-7300; Thermo Fisher Scientific), mouse monoclo-
nal antibody anti-CLDN5 (1:50, 35-2500; Thermo Fisher 
Scientific), and rat polyclonal antibody anti–VE-cadherin 
(1:100, 550548; BD Pharmingen) overnight at room tem-
perature. For VEG FR2 phosphorylation, BMECs were grown 
to subconfluence on collagen-coated cover glass and fixed 
in methanol for 30 min at 4°C, followed by cold acetone 
(maintained at −20°C before use) for 1 min at room tem-
perature, and incubated with anti-pVEG FR2Tyr1175 antibody 
(1:100; Cell Signaling Technology). Cells were washed four 
times in PBS and incubated for 1 h at room temperature with 
a suitable Alexa Fluor–coupled secondary antibody (1:300; 
Thermo Fisher Scientific) in PBS. Cell nuclei were stained 
with DAPI and mounted with Fluoromount-G mounting 
medium (SouthernBiotech).
rnA extraction and qrt-Pcr
Primary BMECs, HUV ECs, and freshly isolated brain micro-
vasculature total RNA were isolated using TRIzol reagent, 
according to the manufacturer’s protocol (Thermo Fisher 
Scientific). For gene expression analysis, single-stranded 
cDNA was produced from 10 ng total RNA of BMECs using 
SuperScript III First-Strand synthesis and random primers 
according to the manufacturer’s protocol (Thermo Fisher 
Scientific). Kapa SybrFast qPCR kit (Kapa Biosystems) and 
thermal cycler (CFX96 Real-Time System; Bio-Rad) were 
used to determine the relative levels of the genes analyzed 
(primer sequences are shown in Table S1) according to the 
manufacturer’s protocol. Actin mRNA levels were used as in-
ternal control, and the 2-ΔΔCT method was used for analysis of 
the data. Each control value (Krit1fl/fl) was normalized to 1, 
and Krit1ECKO values were relative to control.
Genome-wide rnA sequencing
The quantity (ND-1000 spectrophotometer; NanoDrop 
Technologies) and quality (TapeStation; Agilent) of total 
RNA were analyzed. RNA libraries were generated using Il-
lumina’s TruSeq Stranded mRNA Sample Prep kit using 400 
ng RNA. RNA libraries were multiplexed and sequenced 
with 100-bp paired single-end reads (SR100) to a depth of 
∼30 million reads per sample on an Illumina HiSeq2500. Fastq 
files from RNA-seq experiments were mapped to individual 
genomes for the mouse strain of origin using STAR with 
default parameters (mm10 for C57BL/6J; Dobin et al., 2013). 
Reproducibility between samples was analyzed using the ir-
reproducibility discovery rate tool (Li et al., 2011). Homer 
(Heinz et al., 2010) was used for further analysis. To measure 
gene expression, analyze repeats (with the option RNA and 
condense genes) was used along with the default parameters. 
Subset-specific expression was defined with a fourfold dif-
ference in expression between two experiments. Genes with 
fewer than 16 tag counts were defined as not expressed. To 
map subset-specific peaks to gene expression, only expressed 
genes were considered. Differential expression was defined 
by a fold change of at least 1.5-fold averaging over replicates 
(P < 0.05) and used for gene ontology annotation analysis 
with David Bioinformatics (Huang et al., 2009; Eichenfield 
et al., 2016). Sequencing data have been deposited in Gene 
Expression Omnibus (GEO) under accession no. GSE85657.
Whole-mount retinal staining
Eyes were harvested and fixed in PFA for 20 min at room 
temperature. Eyes were washed four times with PBS, and ret-
inal whole-mount preparations were permeabilized, blocked 
using blocking buffer (PBS, 1% BSA, and 0.5% Triton X-100), 
and incubated at 4°C overnight for tight junction and 2 d 
for KLF4 staining. For tight junctions and adherens junction 
staining, whole-mount preparations were incubated with 
rabbit polyclonal antibody anti–ZO-1 (1:50), mouse mono-
clonal antibody anti-CLDN5 (1:80), and rat polyclonal an-
tibody anti–VE-cadherin (1:100) in PBS overnight at room 
temperature. For KLF4 and TSP1 staining, whole-mount 
preparations were incubated with goat polyclonal antibody 
anti-KLF4 (1:100, AF3158; R&D Systems) and rabbit poly-
clonal antibody anti-TSP1 (1:500; Zhang and Lawler, 2007; 
Lawler and Lawler, 2012) in PBS at room temperature for 1 
d followed by 4°C for 2 d. Preparations were washed three 
times in PBS and three times in Pblec buffer (PBS, 1 mM 
CaCl2, 1 mM MgCl2, 0.1 mM MnCl2, and 1% Triton X-100) 
and incubated with isolectin B4 FITC (1:80, L2895; Sig-
ma-Aldrich) or Alexa Fluor 647 (1:80, I32450; Thermo Fisher 
Scientific) conjugated, as indicated, in Pblec buffer at 4°C 
overnight. Preparations were incubated at room temperature 
for 2 h with suitable secondary anti-rabbit Alexa Fluor 594, 
anti-goat Alexa Fluor 488, and anti-mouse Alexa Fluor 647 
antibodies (1:250; Thermo Fisher Scientific) in PBS. Retinal 
whole-mount preparations were washed five times in PBS 
and flat-mounted using Fluoromount-G (SouthernBiotech).
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Immunohistochemistry
P7 Krit1ECKO and littermate control Krit1fl/fl mice were 
perfused with HBSS containing 0.5% BSA to rinse out 
the blood, and brains were isolated and fixed in 4% PFA at 
4°C overnight. After cryoprotection in sucrose and freezing, 
12-µm sections of cerebellar tissue were cut onto Superfrost 
Plus slides (12-550-15; VWR International). The preparation 
was blocked and permeabilized using permeabilization buffer 
(PBS, 5% goat serum, 0.5% Triton X-100, and 0.5% BSA) 
for 2 h and incubated with rabbit polyclonal antibody an-
ti-TSP1 (1:1000; Lawler et al., 1998), rat polyclonal antibody 
anti-PEC AM1 (1:100, 553370; BD PharMingen), rabbit 
polyclonal antibody anti–ZO-1 (1:120), mouse monoclonal 
antibody anti-CLDN5 (1:100), or rat polyclonal antibody 
anti–VE-cadherin (1:100) in PBS. All antibodies were incu-
bated at room temperature overnight in a humidified box. 
Human tissue was obtained after informed consent from 
patients undergoing lesion resection, under protocol #10-
295-A, approved by the University of Chicago Institutional 
Review Board. Human tissue, CCM1 lesions, and lesion-free 
brain tissues were snap-frozen and sectioning using a cryostat 
(Leica). Specimens were fixed in 4% PFA at room tempera-
ture for 15 min and washed three times in PBS. The speci-
mens were blocked and permeabilized using permeabilization 
buffer for 3 h and incubated with rabbit polyclonal antibody 
anti-TSP1 (1:1,000) and goat polyclonal antibody anti–col-
lagen IV (1:100, AB769; Millipore) in PBS at room tem-
perature overnight. Preparations were washed four times in 
PBS and incubated at room temperature for 1 h with suitable 
secondary anti-rabbit Alexa Fluor 594, anti-goat Alexa Fluor 
488, anti-rat Alexa Fluor 488, and anti-mouse Alexa Fluor 
647 antibodies (1:300; Thermo Fisher Scientific) in PBS. Cell 
nuclei were stained with DAPI (SouthernBiotech). 
Image acquisition and quantitative analysis
The slides were viewed with a high-resolution SP5 confocal 
microscope (Leica Microsystems), and the images were cap-
tured with Leica application suite software (Leica Microsys-
tems). For BMEC confocal microscopy, five images in z-stacks 
up to 4.5 µm in depth were acquired with a 60× oil-immer-
sion objective and projected onto one image. For cerebellar 
tissue and retina confocal microscopy, six images in z-stacks 
up to 8 µm (brain) or 6 µm (retina) in depth were acquired 
with a 20× objective or six images to 6 µm in depth were 
acquired with a 60× oil-immersion objective and projected 
onto one image. The quantification analysis was performed 
using Volocity software on high-resolution confocal images. 
Western blot analysis
BMECs or HUV ECs as indicated were grown to confluence 
on collagen-coated six-well plates, whereas cerebellar frozen 
tissue was immersed in liquid nitrogen and pulverized with a 
tissue crusher. Cells and tissue were lysed using lysis solution 
containing 100 µl RIPA buffer (25 mM Tris-HCl, pH 7.6, 
150  mM NaCl, 1% Nonidet P-40, 1% sodium deoxycho-
late, and 0.1% SDS) and a mixture of inhibitors (Roche) and 
1 mM sodium orthovanadate. Protein concentration was de-
termined using a Micro BCA protein assay kit (Pierce). Cell 
lysates were diluted in Laemmli buffer solution at 95°C for 
5 min. 25 µg total protein was resolved on 4–20% polyacryl-
amide gels (Thermo Fisher Scientific) in SDS-PAGE buffer 
and transferred onto nitrocellulose membranes (Amersham) 
using a wet transfer system (Bio-Rad). Membranes were 
blocked with blocking WB solution (PBS, 10% nonfat milk, 
and 0.05% Tween-20) for 1 h and incubated in the presence 
of rabbit polyclonal antibody anti-TSP1 (1:500, ab85762; 
Abcam), anti–ZO-1 (1:150), rat polyclonal antibody anti–
VE-cadherin (1:75), rabbit polyclonal antibody anti–clau-
din-5 (1:170, 34-1600; Thermo Fisher Scientific), rabbit 
polyclonal anti-VEG FR2 (1:200; Cell Signaling Technology; 
1:200; Santa Cruz Biotechnology), and rabbit monoclonal 
anti-VEG FR2pTyr1175 (1:120; Cell Signaling Technology) 
at 4°C overnight. After several washes, membranes were in-
cubated with the appropriate IRDye/Alexa Fluor–coupled 
secondary antibody (1:10,000; Li-COR) and imaged using 
an infrared imaging system (Odyssey; Li-COR). Blots were 
processed using Image Studio Lite software (Li-COR). As a 
control for protein loading, mouse antibodies against actin 
(1:5,000, A1978; Sigma-Aldrich) were used.
Micro-ct scan image
P7 Krit1ECKO, Krit1ECKO;TSP1+/−, Krit1ECKO;TSP1−/−, and lit-
termate control Krit1fl/fl, Krit1fl/fl;TSP1+/−, Krit1fl/fl;TSP1−/− 
mice were killed, and brains were removed and dropped into 
10% neutral buffered formalin (Sigma-Aldrich). Brains were 
soaked in 50 ml of 1.25% Lugol iodine (Thermo Fisher Sci-
entific) for 96  h. Imaging data acquisition was performed 
using the Phoenix v|tome|x s 180/240 micro-CT scanner 
system (General Electric), and hyperdense CCM lesions were 
computationally segmented with the AMI RA 5.5 software 
platform (FEI; Girard et al., 2016).
Expression constructs and shrnAs
To generate the KLF2 and KLF4 constructs, a plasmid tem-
plate encoding KLF2 (50786; Addgene) and KLF4 (19764; 
Addgene) were amplified by PCR to place them down-
stream of mouse PGK promoter and fuse to IRES-puromy-
cin resistance gene into pLVX vector (Clontech). KLF2- and 
KLF4-expressing lentiviral particles were prepared by cotrans-
fection of pLVX;PGK-KLF2 or pLVX;PGK-KLF4 with 
pMDLg/pRRE, pRSV-Rev, and pMD2.G in HEK293T 
cells. Oligos for ShKRIT1 (clone TRCN0000072879, tar-
get sequence 5′-CGG GTA GAT AAA GTG GTA ATA-3′) is 
based on the public TRC (RNAi Consortium; Broad In-
stitute) library and cloned into pLKO.1 using EcoRI and 
Age1 restriction sites. For KLF2, KLF4, or shRNA delivery, 
HUV ECs were grown to 80% confluence on gelatin-coated 
six-well plates and transduced with lentiviral particles. 72 h 
after infection, HUV ECs were prepared for RNA or protein 
analysis (described above).
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Statistical analysis
Data are expressed as means ± SEM. For all experiments, the 
number of independent experiments (n) is indicated. Analy-
ses of brain and retina experiments were performed blinded. 
The sample sizes were estimated with two-sample t test (two-
tailed). The pooled standard deviation was used to account for 
unequal variances in the two groups (vehicle or 3TSR). Two-
tailed unpaired Student’s t test was used to determine statisti-
cal significance. For multiple comparisons, one-way ANO VA 
followed by Tukey’s post hoc test was used. For survival rate 
analysis, long-rank test was performed using SAS Software.
online supplemental material
Fig. S1 shows RNA-seq analysis of BMEC transcriptome 
after acute genetic inactivation of Krit1. Fig. S2 shows 
acute loss of KRIT1 decreases tight junctions in BMECs. 
Fig. S3 (related to Fig.  4) shows that 3TSR prevents VEG 
FR2-Tyr1175 phosphorylation in human endothelial cells. 
Fig. S4 shows that 3TSR does not activate TGF-β signal-
ing in Krit1ECKO. Table S1, included as an Excel file, shows 
primers used for RT-qPCR.
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